This site is intended for healthcare professionals
Guidelines
  • Home
  • /
  • Guidelines
  • /
  • CIDP
  • /
  • Current clinical management of CIDP with immunoglo...
Guideline

Current clinical management of CIDP with immunoglobulins in France: An expert opinion

Read time: 1 mins
Last updated:1st Oct 2023
Author: Cintas P, et al.
Availability: Free full text
Status: Current
Current clinical management of CIDP with immunoglobulins in France: An expert opinion


Treatment strategies in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) must be adapted on a case-to-case basis. Validated and reproducible tools for monitoring treatment response are required at diagnosis, when initiating treatment and throughout follow-up. A task force of French neurologists, experts in neuromuscular disease reference centers, was assembled to provide expert advice on the management of typical CIDP with intravenous immunoglobulins (Ig), and to harmonize treatment practices in public and private hospitals. The task force also referred to the practical experience of treating CIDP with Ig at the diagnostic, induction and follow-up stages, including the assessment and management of Ig dependence, and following the recommendations of the French health agency.


Read full Guideline